If you’re looking at GLP-1 stock in 2026, you’re not just watching a drug class; you’re watching a mass‑scale rewiring of healthcare economics. The GLP‑1 obesity and diabetes market is projected to grow from about $10.1B in 2026 to roughly $66.6B by 2035, an annual growth rate of about 23%. That kind of runway turns Novo Nordisk (NVO) and Eli Lilly (LLY) into something closer to tech‑style compounders than old‑school pharma.
You’ll walk away knowing:
- The GLP‑1 market context (Ozempic, Wegovy, Mounjaro, Zepbound, oral‑GLP‑1s, and the $10B+ obesity‑only segment).
- Why NVO and LLY are the two leaders, and what each one is doing with manufacturing, formulation, and pricing.
- Which next‑generation challengers (Amgen with MariTide, Viking with VK2735, Roche with CT‑388, and Structure Therapeutics’ oral GLP‑1 pill) could carve out meaningful share.
- What real risks look like: compounding‑pharmacy competition, insurance‑reimbursement battles, side‑effect data, manufacturing‑capacity limits, and M&A volatility.
- How non‑pharma players (bariatric‑surgery equipment makers, food companies) are reacting, plus which ETFs give you indirect exposure (XBI, IBB, FBT, SBIO, ARKG, VOO, VTI, SCHD).
This is a 2026‑style, position‑sizing‑ready guide to GLP‑1 and obesity drug stocks, not a hunch‑based “next‑big‑winner” list.
How big is the GLP‑1 and obesity drug market?
The obesity‑only GLP‑1 market alone is expected to reach about $10.1B in 2026, then grow to roughly $66.6B by 2035. That’s an extremely wide runway for a handful of companies to try to capture volume.
- What’s driving this:
- Rapidly rising global obesity rates.
- Strong clinical evidence for weight loss and cardiometabolic benefits.
- What’s already in motion:
- NVO and LLY already treat tens of millions of patients with Ozempic, Wegovy, Mounjaro, Zepbound, and related products.
This is why GLP‑1 stocks (NVO, LLY, and relevant biotechs) now trade more like growth‑style equities than traditional dividend‑yield pharma.
The two leaders: Novo Nordisk (NVO) and Eli Lilly (LLY)
Novo Nordisk (NVO) – semaglutide dominance
- Key drugs: Ozempic (T2D), Wegovy (obesity), and now an oral semaglutide pill version under FDA review.
- 2026 reality:
- Wegovy pill sales are growing faster than the weekly injectable, but Novo also warned of its first sales drop in the Ozempic/Wegovy line after years of hyper‑growth.
- Strategy and risk:
- Pillification (oral formulations) is supposed to speed uptake and ease dosing, but it also adds pricing pressure and pilot‑programs from insurers.
- The company is still capacity‑constrained; demand can outstrip supply, which supports prices but also attracts regulatory and compounding scrutiny.
If you hold NVO, you are betting on a semaglutide‑based platform that can keep penetrating T2D, obesity, and adjunct indications without getting crushed by pricing or safety shocks.
Eli Lilly (LLY) – tirzepatide and oral GLP‑1
- Key drugs: Mounjaro (T2D), Zepbound (obesity, GLP‑1/GIP).
- 2026 context:
- Zepbound and Mounjaro together generated over $2B in sales in Q1 2026, and demand is so high that Lilly itself says it struggles to keep up.
- Lilly is spending about $9B total on a Lebanon, Indiana GLP‑1 manufacturing plant, which should start output toward the end of 2026 and ramp through 2028. This is the largest manufacturing invest1now.com in the company’s history.
- Pipeline push:
- Lilly is also developing oral GLP‑1 compounds, which could cut dosing friction and open up patients who dislike injections.
LLY is essentially running a Moore’s‑Law‑style capacity build around GLP‑1, while still riding a huge demand wave for injections.
Next‑generation GLP‑1 obesity challengers
If you already own NVO and LLY, you can consider next‑gen players that either try to one‑up the current GLP‑1s or add convenience (dosing, oral route).
1. Amgen – MariTide
- Ticker: AMGN
- Drug: MariTide (maridebart cafraglutide), a once‑quarterly GLP‑1‑like compound for obesity and type 2 diabetes.
- 2026 status:
- Positive Phase II data showed meaningful weight loss and metabolic benefit.
- Amgen is positioning MariTide as a differentiated dosing story (less frequent than weekly or daily injections).
- Risk:
- If weekly GLP‑1s stay cheap and easy to access, quarterly dosing may not be enough premium to justify a separate price.
- There are also competition risk and long‑term safety‑data risk for any new obesity agent.
MariTide is not a binary‑trial bet; it’s a mid‑course correction to the GLP‑1 script, trying to reduce patient burden.
2. Viking Therapeutics (VKTX) – VK2735
- Ticker: VKTX
- Drug: VK2735, a dual GLP‑1/GIP agonist for obesity and metabolic disease.
- 2026 status:
- VK2735’s Phase 2 VENTURE trial showed weight loss of up to 14.7% and a placebo‑adjusted reduction of up to 13.1% after 13 weekly doses.
- Viking has initiated Phase 3 trials (VANQUISH‑1 and VANQUISH‑2) in obese adults, with and without diabetes.
- Risk:
- The company is small‑cap, cash‑consuming, and dependent on Phase 3 success and subsequent FDA approval.
- It’s a classic binary‑drug‑candidate play with a very thin balance sheet.
VKTX is a speculative satellite in a GLP‑1 portfolio, not a core.
3. Roche – CT‑388
- Ticker: RHHBY (OTC‑listed ADR, but Roche is a Swiss large‑cap).
- Drug: CT‑388, a dual GLP‑1/GIP agonist for obesity.
- 2026 status:
- In a Phase II trial, CT‑388 achieved 22.5% lighter average weight vs. placebo at 48 weeks at the highest dose, with 54% of patients reaching non‑obese BMI vs. 13% on placebo.
- The safety profile was broadly consistent with the GLP‑1 class, with no new red flags.
- Risk:
- Even at a large pharma, a single asset rarely moves the needle unless it becomes a multi‑billion blockbuster.
- Given that, CT‑388 is more of an option‑on‑success than a reason alone to own Roche.
4. Structure Therapeutics (GPCR) – oral GLP‑1 pill
- Ticker: GPCR (small‑cap, Nasdaq)
- Drug: A GLP‑1‑based oral obesity pill.
- 2026 status:
- A mid‑stage trial showed up to 11.3% weight loss after 36 weeks, which sent the stock up more than 140% on the news.
- Risk:
- Oral GLP‑1s must match or beat injected drugs on efficacy and safety while still being manufacturable and reimbursable.
- Investors are clearly pricing huge success into GPCR; the stock can give back half its gain on any setback.
GPCR is a pure‑event stock with a high‑quoted valuation tied directly to Phase 3 readouts.
Real risks hanging over GLP‑1 investing
GLP‑1 obesity drugs are not a one‑way trajectory up. Several secular risks are real and already in motion.
Compounding‑pharmacy competition
- What’s happening:
- Compounding pharmacies and digital‑health firms (like Hims & Hers) have offered “Wegovy‑like” GLP‑1 mixes at lower prices.
- In 2026, the FDA and Novo Nordisk are both taking legal and enforcement action against some of these operations, arguing that quality, safety, and efficacy are not guaranteed.
- What it means for you:
- Short‑term price suppression and uncertainty if the market stays fragmented.
- Long‑term possible consolidation back to branded, regulated products if regulators crack down.
Insurance reimbursement battles
- 2026 coverage shift:
- Medicare is expanding coverage of GLP‑1 drugs for obesity when paired with comorbidities like diabetes or heart disease, starting in April 2026.
- Many commercial insurers and some Medicaid plans are shrinking coverage for weight‑loss‑only use, often moving drugs to restricted tiers or dropping them entirely unless an employer pays extra.
- Investment implication:
- Growth is not uniform; it depends on who pays and what they certify as medical necessity.
- Volume can swing up or down based on payers’ quarterly decision‑making, not just trial data.
Side‑effect and long‑term safety data
- Known issues:
- GLP‑1s can cause nausea, GI symptoms, and rare but serious pancreatitis or gallbladder‑related events.
- Because these drugs are relatively new, long‑term cardiovascular and safety questions remain.
- What to watch:
- Any regulatory update, new FDA warning, or big‑study signal can trigger sharp stock moves in NVO, LLY, AMGN, or small‑cap developers.
Manufacturing and capacity limits
- The bottleneck:
- Both Novo and Lilly have struggled to keep up with demand, even as they pour billions into new manufacturing plants.
- Risk:
- If capacity lags, price pressure intensifies and payors start steering toward cheaper or alternative therapies.
- Conversely, if capacity ramps smoothly, you see volume‑based earnings growth without the same kind of margin erosion.
Indirect plays: bariatric surgery, food, and lifestyle companies
GLP‑1s are not just pharma wins; they are structural headwinds or tailwinds for other sectors.
Medical‑device companies losing bariatric‑surgery revenue
- Trend:
- Bariatric‑surgery volumes are falling in the U.S. as more patients choose GLP‑1 agents over surgery.
- Who’s affected:
- Companies that manufacture surgical instruments, staplers, monitoring systems, and anesthesia‑service bundles tied to bariatric procedures see softer demand.
- Investment angle:
- If you hold medical‑device stocks, you should ask whether obesity‑surgery exposure is a tailwind or drag in a high‑GLP‑1‑penetration world.
Food and consumer‑staples adjustment
- What’s shifting:
- Millions of people on GLP‑1 meds report lower appetite, reduced snacking, and different eating patterns.
- Fast‑food chains, snack‑makers, and “junk‑food” brands may see lower impulse purchases and shifts toward smaller‑portion, higher‑value‑per‑bite products.
- How to read it:
- GLP‑1 is a behavioral undercurrent for food‑stocks, not a direct driver, but it can nudge sales mix and product‑development priorities.
How to get GLP‑1 exposure via ETFs and accounts
If you want to how to invest in GLP‑1 stocks without building a micro‑biotech book, you can use ETFs and broad indices.
- Direct biotech ETFs:
- XBI (SPDR S&P Biotech ETF, 0.35% fee) – small‑ and mid‑cap‑heavy, includes many GLP‑1‑adjacent biotechs.
- IBB (iShares Biotech ETF, 0.45% fee) – holds NVO‑like large‑caps plus clinical‑stage obesity players.
- FBT (First Trust Biotech ETF) – narrow 30‑stock, more volatile, can concentrate on near‑term catalyst‑rich names.
- SBIO (ALPS Medical Breakthroughs) – focuses on Phase 2–3 drugs, which includes many weight‑loss candidates.
- Broad‑market ETFs that still capture LLY and NVO:
- VOO (0.03%), VTI (0.03%), SCHD (0.06%), etc., give you GLP‑1 exposure as a small slice of a diversified index rather than a thematic bet.
Best account placement
- Roth IRA or Traditional IRA:
- Good for long‑term GLP‑1 stock or ETF positions you expect to compound over 10–20 years.
- Taxable brokerage:
- Works for shorter‑term trades or rebalancing, but remember capital‑gains rules (0%, 15%, 20% long‑term; up to 37% short‑term in 2026).
2026 IRA limits are $7,000 if under 50, $8,000 catch‑up, which sets how much space you can carve for LLY, NVO, AMGN, XBI, or IBB inside retirement accounts.
How to size GLP‑1 in your portfolio
GLP‑1 and obesity‑drug stocks are high‑beta satellites, not core.
- Reasonable allocation band:
- Many multi‑asset shops limit GLP‑1‑style pharma/biotech exposure to roughly 5–10% of your total equity portfolio.
- Example mix (total equity $100,000):
- $70,000–$80,000 – VTI, VOO, VXUS, BND, SCHD, SPY, QQQ, VNQ, AVUV, JEPI.
- $5,000–$10,000 – LLY, NVO, AMGN, VKTX, GPCR, XBI, IBB, FBT, or SBIO in some combination.
If you want to see how a 5–10% GLP‑1 slug would have affected overall volatility and drawdowns, you can model it in an **Invest
